This study will investigate the benefits of administering celecoxib (Celebrex), a selective
cyclooxygenase -2 (COX-2) inhibitor, in treating osteoarthritis (OA) subjects undergoing
elective unilateral primary total knee arthroplasty (TKA) from the pre-operative phase to the
management of post total knee replacement pain, and through the 6 weeks of physical therapy
and rehabilitation.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.